Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2025
NEW YORK, Dec. 5, 2017 /PRNewswire/ -- According to the latest report of DelveInsight, "Cytomegalovirus (CMV) Infections- Market Insights, Epidemiology and Market Forecast-2025", At least 60% of the US population has been exposed to CMV, with a prevalence of more than 90% in high-risk groups (e.g., male homosexuals).
Read the full report: https://www.reportlinker.com/p04985954
As per the estimates, the prevalence of CMV is higher in the United States as compared to EU5 and Japan. The total prevalence and number of diagnosed cases for CMV infections are expected to experience a modest growth in the coming years. In 2016 around 0.5 billion CMV cases were recorded in the 7MM.
Even after such high prevalence, CMV Infection market is flooded with Generic products as the top-selling drugs have gone off-patent. Most recent gone off patent drug was Valcyte, which lost its patent in 2013 and 2015 in the US and Europe, respectively. This overflow of market by the generic drugs has negatively impacted the growth of the CMV Infection market. DelveInsight expects an increase in market size after 2017 attributed to the increase of the patient pool for CMV infection and the expected launch of one Quinazoline -based inhibitor (Letermovir-received FDA and EMA approval in November 2017) and one novel vaccine: ASP0113 (Formerly known as TransVax). Upcoming therapies are still keeping the hopes high and are expected to drive the CMV market in the coming future. The total market size of CMV infection is expected to increase at a CAGR of 6.09% during 2015-2025.
The latest report has covered a detailed description of Diagnosis, Management, and Treatment Algorithm. Complete Pipeline drugs profiling covering each and every phase of development with clinical trials data. Total market size of CMV is provided covering the 7MM to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population details are provided covering the 7MM to better understand the major market scenario. Details about all the possible market drivers and barriers are also provided to better understand the areas of improvement and to plan the strategies accordingly.
Key Coverage and Benefits
• The Report includes the prevalent population and how will it change over the next eight years.
• Coverage of key Cytomegalovirus (CMV) Infection sub-populations and its prevalent or incident cases
• Prevalent or incident cases segmented by age and sex.
• The key differences in epidemiology patterns across the seven market segments.
Reasons to buy
• Developing business strategies by understanding the trends shaping and driving the global Cytomegalovirus (CMV) Infection market.
• Identifying prevalent patient populations as well as risk factors in the global Cytomegalovirus (CMV) Infection market will help to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Cytomegalovirus (CMV) Infection therapeutics in each of the markets covered.
Read the full report: https://www.reportlinker.com/p04985954
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article